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Objective. To describe the occurrence of CRKP infections in a 
tertiary care hospital and to analyse the allelic profiles of the 
clinical strains involved and the most frequent carbapenemases.
Design. The study analyzed cases of infection due to CRKP in 
the period 2013-2014; 147 cases  were recorded, most of which 
(82.31%) were in-hospital infections.
Setting. A hospital in northern Italy.
Methods. We retrospectively collected: data on patient charac-
teristics and the microbiological characteristics of CRKP. Iso-
lates from 72 of the in-hospital cases underwent molecular typing 
(MLST); in addition, in each isolate, a procedure for the detection 
of the blaKPC gene was carried out. 
Results. The in-hospital death rate was 24.0% in 2013 and 37.5% 
in 2014. However, the difference between these two values did not 
prove statistically significant (P > .05).
Analysis of mortality revealed that bloodstream infections were 
more frequently associated with death than other infections 
(c2 = 14.57, P < .001). The age-adjusted Cox proportional haz-
ard model revealed that the patients with bacteremia due to CRKP 
had a 3-fold higher risk of death (HR 3.11; 95% CI 1.66 - 5.84, 
P< .001) than those with infections of other sites.
MLST revealed that the prevalent allelic profile was ST 512 
(79.62%); the most frequent carbapenemase was KPC-3 (83.8%).
Conclusions. Our results are in line with those of recent studies, 
which have shown that the spread of CRKP in Italy is a matter of 
concern and that further efforts have to be made to prevent the 
potential dissemination of carbapenemase-producing clones of K. 
pneumoniae, whenever possible.
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Summary
Introduction
Since the 1970s, the selective pressure exerted by antibiot-
ics has given rise to bacterial species that are increasingly 
resistant, and the last 20 years have seen a dramatic rise 
in the number of multi-resistant pathogenic strains  [1]. 
Multidrug-resistant Klebsiella pneumoniae is one of the 
leading causes of nosocomial infection worldwide. It 
causes urinary tract infections (UTIs), pneumonia and in-
tra-abdominal infections in hospitalized immunocompro-
mised patients with severe underlying diseases [2] and is 
responsible for roughly 15% of Gram-negative infections 
in hospital intensive care units (ICUs) [3].
After the spread of strains resistant to beta-lactams at 
the end of the 20th century, the diffusion of isolates of K. 
pneumoniae resistant to carbapenems and colistin is now 
reducing treatment options and the containment of infec-
tions [4]. In recent years, carbapenem-resistant Klebsi-
ella pneumoniae (CRKP) has become a widespread con-
cern and carbapenemase production mediated by blaKPC 
is the most prevalent mechanism conferring resistance to 
carbapenems [5]. Outbreaks of CRKP have increasingly 
been reported in various healthcare settings [4, 6, 7], in-
cluding long-term acute care hospitals [8].
Risk factors for colonization and infection with CRKP are 
similar to those associated with other multidrug-resistant 
organisms [9]. Lengthy hospitalization, antibiotic use, in-
vasive procedures and admission to the ICU [8] are as-
sociated with an increased risk of acquisition of CRKP.
Mortality rates due to infections caused by CRKP are 
high, ranging from 26% to 44% and reaching 70% in 
cases of bacteremia [10-12]. However, deaths reported to 
be associated with carbapenem-resistant K. pneumoniae 
have included several cases in which the patient had a 
severe underlying disease, and it is frequently difficult to 
determine whether carbapenem-resistant K. pneumoniae 
infection was the cause of death. 
The aim of the present study was to describe the occur-
rence of CRKP infections in a northern Italian hospital 
and to analyse the allelic profiles of the clinical strains 
involved and the most frequent carbapenemases.
Materials and methods
Setting
The study was conducted in a nationally renowned, 
highly specialized Northern Italian hospital organized 
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in accordance with treatment intensity. Structured in pa-
vilions, the hospital has 458 beds (mainly located in 3- 
and 4-bed rooms) and each year carries out over 15,000 
ordinary hospitalizations and more than 8600 medical 
procedures in Day Hospital and Day Surgery settings. 
Study design
The study retrospectively analyzed cases of infection 
due to CRKP in the period 2013-2014. 
Patients who were identified as having CRKP infections 
within the first 72 h of admission were defined as com-
munity-associated cases or, if they had been exposed to 
healthcare settings during the previous three months, im-
ported healthcare-associated cases. Clinical episodes of 
infection were considered to be hospital-acquired if they 
were not present at the time of hospital admission and 
appeared 72 hours after admission.
A record was made of each case patient’s age, gender, 
history of hospitalizations, antibiotic treatments, dura-
tion of hospitalization, the date of the first CRKP de-
tection, the site of infection and co-infections, invasive 
procedures and outcomes.
If a positive patient had been transferred from one ward 
to another, acquisition of the infection was attributed to 
the ward in which the diagnosis of infection was made, 
as the exact site of acquisition could not be determined.
The incidence of infections was calculated per 1000 
days of hospitalization.
Classification of patients according  
to infection risk and type of isolation applied
Patients were grouped into two categories of infection 
risk: high-risk and medium-risk according to the charac-
teristics of the patient and the site of infection. Patients 
were deemed to be at high risk if they presented one or 
more of the following characteristics: presence of excre-
tions/secretions at the infection site, confinement to bed, 
lack of self-sufficiency, and great need for assistance. 
Patients in this category underwent structural or cohort 
isolation; if this was not possible, functional isolation 
was implemented. 
Patients were defined as being at medium risk if they 
presented one or more of the following characteristics: 
presence of reduced secretions or excretions at the infec-
tion site, capability of temporal and spatial orientation, 
ability to cooperate, self-sufficiency, and low-medium 
need for assistance. These patients underwent functional 
isolation.
Microbiologic methods
Bacterial identification and antimicrobial susceptibility 
testing were carried out by means of the Phoenix 100 
Automated Microbiology System (Becton Dickinson 
Diagnostic Systems, USA). 
Confirmatory MIC testing for imipenem, meropenem 
and ertapenem was carried out by means of Etest (bio-
Mérieux SA, France) and the Kirby Bauer disk diffusion 
method [13]. All collected isolates that were confirmed 
to be non-susceptible to imipenem and/or meropenem 
and/or ertapenem according to the EUCAST break-
points  [14] were considered to be Carbapenem-resist-
ant K. pneumoniae and underwent a modified Hodge 
test [15] to confirm carbapenemase production. In addi-
tion, in order to identify which carbapemenase was pres-
ent, PCR for the blaKPC gene was carried out [16].
Biomolecular analysis
The isolates from 72 of the in-hospital cases underwent 
molecular typing by means of the MLST technique 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/
Kpneumoniae.html). This technique involves amplify-
ing and sequencing seven housekeeping genes (rpoB, 
gapA, mdh, pgi, phoE, infB, tonB) and, through com-
parison with the data available in an online databank, 
enables a specific ST (Sequence Type) to be assigned 
to each isolate. The amplification protocol prescribes an 
initial denaturing phase at 94°C for 5 minutes, followed 
by 35 cycles at 94°C for 30 seconds, 50°C for 30 sec-
onds and 72°C for 30 seconds, with a final extension at 
72°C for 5 minutes. 
In addition, in each isolate, a procedure for the detection 
of the blaKPC gene was carried out through the amplifica-
tion and sequencing of a DNA fragment of about 1000bp 
by means of the following primer pairs: blaKPC-Forward 
5’-TGTCACTGTATCGCCGTC-3’ and blaKPC-Reverse 
5’-CTCAGTGCTCTACAGAAAACC-3’. The amplifi-
cation phase consisted of an initial denaturing phase at 
95°C for 5 minutes, followed by 35 cycles at 95°C for 60 
seconds, 55°C for 40 seconds and 72°C for 90 seconds, 
with a final extension at 72°C for 10 minutes. The se-
quences obtained were compared with those available in 
the NCBI database (http://blast.ncbi.nlm.nih.gov/Blast.
cgi), which enabled the blaKPC gene to be characterized.
For both the identification of the Sequence Type and de-
tection of the blaKPC gene, sequencing was carried out by 
means of an Applied Biosystems 3730xl DNA Analyzer 
(Life Technologies, USA).
Infection control measures
In all high-risk patients, rectal swabs were taken by the 
ward nurse on admission to the ward. Cultures were then 
sent directly to the bacteriology laboratory for prompt 
CRKP identification.
The diffusion of the microorganism was monitored by 
means of continuous integrated microbiological sur-
veillance, starting with laboratory data (alert organism 
surveillance). Following laboratory identification of an 
epidemiologically important microorganism, the dedi-
cated software of the surveillance system automatically 
e-mails the data to all the members of the Hospital Infec-
tions Committee, who then implement the interventions 
deemed necessary, with particular regard to the applica-
tion of isolation measures. 
A validated report is simultaneously sent through the 
laboratory information system to the hospital facility in-
volved. 
Antibiotic therapy was instituted after consultation with 
the infectious-disease specialist on the basis of case his-
tory, patients’ clinical features, microbiological isolates 
and antibiotic sensitivities.
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Hospital-wide policies to prevent nosocomial carbap-
enem-resistant Enterobacteriaceae transmissions were 
introduced on the basis of an institutional protocol that 
was developed in accordance with the American Cent-
ers for Disease Control and Prevention (CDC) indica-
tions [17].
Statistical analysis
Statistical analysis was carried out by means of STATA 
SE13TM software (Stata Corp LP, USA). The results 
were analyzed in terms of descriptive statistics, and dif-
ferences between groups were evaluated by means of 
non-parametric chi-square test and Fisher’s mid-P exact 
test.
Kaplan-Meier survival curves were assessed by means 
of a log-rank analysis, to compare overall survival, and 
a COX proportional hazard model, to assess the role of 
possible confounders. A p-value < 5% was considered 
significant.
Results
In the period of observation, 147 cases of CRKP infec-
tion were recorded (75 in 2013 and 72 in 2014) most of 
which (82.31%) were in-hospital infections. 
The overall mean age of the patients was 78.95 ± 12.05 
years (range 26-97 years). Women accounted for 50.34% 
of the patients; their mean age was 81.49 ± 10.51 years 
(range 42-97 years). The mean age of the male patients 
Tab. I. Carbapenem-resistant Klebsiella pneumoniae case characteristics.
Value (%)
Total no. confirmed 147
Unit in which the diagnosis of infection was made
    medical ward 55 (37.41)
    geriatric unit 53 (36.06)
    Surgical ward 30 (20.41)
    ICU* 9 (6.12)
Cases from:
    hospital 121 (82.31)
    Other healthcare facility 13 (8.84)
    Community 13 (8.84)
Invasive procedures correlated with infection 56 (46.28)
    Bladder catheter 42 (75.00)
    CvC§ 5 (8.92)
    erCp^ 3 (5.36)
    Tracheal intubation 2 (3.57)
    percutaneous surgical drainage 2 (3.57)
    Urethral catheter 1 (1.79)
    pIvC° 1 (1.79)
Sites of CrKp infection
    Urinary tract infection 96 (65.31)
    Bloodstream infection 23 (15.64)
    Surgical site infection 15 (10.20)
    Airways 7 (4.76)
    Other 6 (4.09)
Specimen type
    Urine from catheter 65 (44.22)
    Urine 31 (21.09)
    Blood 25 (17.00)
    Other 6 (4.08)
    Bronchial aspirate 4 (2.72)
    Surgical fragment 4 (2.72)
    Abdominal fluid 4 (2.72)
    pus 4 (2.72)
    Skin swab 1 (0.68)
    Wound swab 1 (0.68)
    Bile 1 (0.68)
    expectorate 1 (0.68)
*ICU = intensive Care Unit - §CvC = central venous catheter - ^erCp = endoscopic retrograde Cholangiopancreatography - °pIvC = peripheral Intravenous 
Catheter
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was 76.37 ± 12.99 years (range 26-96 years). The dif-
ference in age between males and females proved to be 
statistically significant (t = 2.6265, P < .01). 
The mean duration of hospital stay was 35.32 ± 25.04 
days (range 1-168).
In 46.28% of the cases of in-hospital infection, the infec-
tion was related to an invasive procedure (Tab. I).
The Age-adjusted Charlson Comorbidity Index revealed 
comorbidity values in the hospitalized patients of 6.21 
and 6.67 in 2013 and 2014, respectively (P >.05).
Over the two-year observation period, 47.62% of the 
CRKP-infected patients were deemed at high risk. On 
considering the two years separately, a statistically sig-
nificant difference emerged (Χ2  =  16.0481, P  <  .001) 
between the percentage of patients classified as being 
at high infective risk in 2013 (32.00%) and in 2014 
(63.89%). 
A total of 70.77% of patients were hospitalized in 4-bed 
rooms, 17.69% in 2-bed rooms and 7.69% in single 
rooms. It was possible to hospitalize only 3.85% of 
patients in rooms with dedicated bathrooms (1.54% in 
4-bed rooms, 1.54% in 2-bed rooms and 0.77% in single
rooms).
Table I reports some characteristics of the cases of infec-
tion examined: the unit in which the diagnosis of infec-
tion was made, the provenance of the cases, the inva-
sive procedures performed, the sites of infection and the
specimen type.
The incidence of infections was 0.442 pts/1000 days of 
hospitalization in 2013, and 0.513 pts/1000 days of hos-
pitalization in 2014 (P > .05). 
In the entire period of observation, we recorded 24 cases 
of coinfection due to: Escherichia coli, Enterococcus 
faecalis, Pseudomonas aeruginosa, Staphylococcus au-
reus, Acinetobacter baumannii, Enterococcus faecium, 
Proteus mirabilis, Corynebacterium striatum, Entero-
coccus casselliflavus, Moraxella morganii, Serratia 
marcescens, and Staphylococcus haemolyticus. Among 
these microorganisms, we identified ESBL-positive 
strains of E. faecium, E coli, P. mirabilis and P. aeru-
ginosa; VRE strains of E. casseliflavus and E. faecalis, 
and strains of MRSA.
With regard to patient outcomes over the two years of 
observation, 30.61% of the patients died in hospital; 
12.24% were transferred to other units in the hospi-
tal; 0.68% were transferred to other hospitals; 19.73% 
were transferred to a residential facility; 4.76% were 
discharged with home assistance, and 31.97% were dis-
charged home without assistance.
The in-hospital death rate was 24.0% in 2013 and 37.5% 
in 2014. However, the difference between these two val-
ues did not prove statistically significant (P > .05).
Analysis of mortality by means of Kaplan-Meier sur-
vival curves revealed that bloodstream infections were 
more frequently associated with death than were urinary 
infections and other infections (Fig. 1), the difference 
being statistically significant (Χ2 = 14.57, P < .001). 
Of the 23 cases of bloodsteam infections, 14 (12 hospital 
and 2 community) were cases of primary bacteremia; 10 
of these patients died. The remaining 9 cases were sec-
ondary bacteremia, all nosocomial; 5 of these patients 
died. The mean age of the patients with primary bactere-
mia was 75.36 ± 10.70 years (range 58-90), while that of 
the patients with secondary bacteremia was 77.89 ± 9.57 
years (range 63-92).
The age-adjusted Cox proportional hazard model re-
vealed that the patients with bacteremia due to CRKP 
Tab. II. Antibiogram for carbapenem-resistant Klebsiella pneumo-
niae cases reported.
Antimicrobial No. resistant/No. tested (%)
Aztreonam 145/147 (99)
Amikacin 45/55 (82)
Amoxicillin-
clavulanic acid
145/147 (99)
Colistin 38/145 (26)
Cefalexine 91/92 (99)
Cefepime 102/147 (99)
Cefixime 91/92 (99)
Cefotaxime 145/147 (99)
Ceftazidime 145/147 (99)
Cefuroxime 144/145 (99)
Ciprofloxacin 145/147 (99)
Fosfomycin 17/130 (13)
gentamicin 25/147 (17)
Levofloxacin 55/55 (100)
moxifloxacin 91/92 (99)
Ampicillin 147/147 (100)
piperacillin 55/55 (100)
piperacillin-
tazobactam
145/147 (99)
Tygecicline 5/41 (12)
Tobramycin 135/147 (92)
Thrimetoprim 76/94 (81)
Thrimetoprim-
sulfamethoxazole
112/147 (76)
Fig. 1. Kaplan-meier curves of survival probability of patients with 
carbapenem-resistant Klebsiella pneumoniae infection, by infec-
tion site.
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detected in October 2008. In 2011, the European Anti-
microbial Resistance Surveillance Network (EARS-Net) 
reported that Italy was one of the most seriously affected 
countries in Europe, with a worrisome increasing trend 
in CPKP [22-24].
These strains are implicated in nosocomial outbreaks 
and cause serious infections in ICUs. Moreover, recent 
national data have shown that CRKP is more frequently 
isolated from patients outside ICUs, and often from those 
admitted to geriatric or internal medicine wards [25, 26]. 
In the present study, we documented the occurrence of 
147 cases of CRKP infections in a Northern Italian hos-
pital. These cases were chiefly detected in medical wards 
(37.41%) and geriatric units (36.06%), followed by sur-
gical wards (20.41%) and ICUs (6.12%). These wards 
are also frequently involved in CRKP infections in other 
countries. Indeed, Poulou et al. [27] reported that, of the 
73 CRKP infections registered between 2009 and 2011 
at a university hospital in Greece, 43.8% were identified 
in the ICU, 41.1% in medical wards and 15.1% in sur-
gical wards. Moreover, Kanerva described an outbreak 
of carbapenemase-producing Klebsiella pneumoniae in 
a primary care hospital in Finland; this was confined 
to one geriatric ward and involved 142 patients with a 
mean age of 83 years [28].
Most of the CRKP-positive cases described in the present 
study involved elderly patients (mean age 78.95 ± 12.05 
years). The Age-adjusted Charlson Comorbidity Index 
revealed values of underlying comorbidity in hospital-
ized patients of 6.21 in 2013 and 6.27 in 2014 (P > .05), 
reflecting a high level of complexity of assistance, which 
remained fairly constant throughout the observation pe-
riod. 
These findings are in line with those of recent studies, 
which have shown that the spread of CRKP in Italy is 
becoming a matter of concern in areas of care that were 
generally considered to be at lower risk. Moreover, one 
of the principal targets of CRKP is the population of ge-
riatric patients [24, 29, 30], who display a high degree of 
clinical complexity and a large number of comorbidities 
and are frequently bedridden or cognitively impaired. 
Thus, frailty and comorbidity are, in themselves, a major 
risk factor for CRKP colonization, together with those 
already described in the literature (length of hospitaliza-
tion, number of previous hospitalizations and/or previ-
ous ICU stays, previous antibiotic use, severity of ill-
ness, etc) [21, 30, 31].
In a large, retrospective, matched (1:2) case-control study 
in five Italian hospitals, Tumbarello et al. identified risk 
factors for CRKP infections; the strongest predictor of 
CRKP isolation was a history of ≥ 2 previous acute-care 
hospitalizations in the year before the index culture. Iso-
lation was also associated with indwelling medical de-
vices, such as urinary catheters, central venous catheters 
(CVCs) and surgical drains  [21]. Invasive procedures 
are well-known risk factors for infection by CRKP [32]; 
indeed, the formation of biofilms on these devices is im-
portant in the pathogenesis of these bacteria [33, 34]. In 
46.28% of the cases of in-hospital infection recorded in 
the present study, it was possible to correlate the infec-
had a 3-fold higher risk of death (Hazard ratio  [HR], 
3.11; 95% CI 1.66-5.84, P < .001) than those with infec-
tions of other sites.
With regard to the results of antimicrobial susceptibil-
ity testing, the data on the resistance of the strains are 
reported in Table II; 26% of strains proved resistant to 
colistin. The antimicrobial ertapenem was the most fre-
quently reported carbapenem tested for susceptibility 
(100%), followed by meropenem (98.6%) and imipenem 
(48.3%). 
Genotyping of the strains by means of MLST revealed 
that the prevalent allelic profile was ST 512 (79.62%), 
followed by ST 307 (8.97%), ST 101 (3.85%), ST 147 
(3.85%), ST 258 (3.85%), ST 15 (1.28%), and ST 45 
(1.28%). Detection of the blaKPC gene revealed that the 
most frequent carbapenemase was KPC-3 (83.8%) and 
that KPC-2 was less common (16.2%).
With regard to blaKPC gene detection in relation to the al-
lelic profiles, it emerged that STs 258, 101, 147, 15 and 
45 displayed only blaKPC-2; that ST 307 were associated 
only to blaKPC-3; that most ST 512 hosted the blaKPC-3 
gene (98%), and that only a small portion hosted blaK-
PC-2 (2%) (Fig. 2).
Discussion and conclusions
The emergence and spread of Klebsiella pneumoniae 
harboring carbapenemases have given rise to several 
problems regarding infection control and treatment.
Carbapenamase-associated resistance is alarming for 
a number of reasons. The presence of these enzymes, 
in addition to signifying resistance to carbapenems, is 
also associated with additional mechanisms of resis-
tance to other antibiotic classes which, together, result 
in microbes that are highly multidrug resistant and in 
some cases panresistant  [18-20]. Consequently, they 
are invariably associated with high treatment failure 
rates [21].
CRKP has rapidly become a major health concern for 
hospitalized patients in industrialized countries, and in-
fection rates have been dramatically increasing world-
wide over the past 10 years. The first case of carbapen-
emase-producing Klebsiella pneumoniae in Italy was 
Fig. 2. Percentage distribution of carbapenemases in the various 
allelic profiles isolated
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tive event with an invasive procedure. Specifically, 75% 
of these cases occurred in patients with a urinary cath-
eter; and indeed, the principal specimen type from which 
CRKP was isolated was catheter urine (44.22%). Lower 
percentages of infections related to invasive procedures 
were associated with CVCs (8.92%), endoscopic retro-
grade cholangiopancreatography (5.36%), and various 
other indwelling medical devices (overall, 10.72%).
During the two-year observation period, we registered 
an increase in the incidence of new clinical cases per 
1,000 patient days. Fortunately, however, this increase 
did not reach statistical significance (0.442 cases/1,000 
patient days in 2013 versus 0.513 cases/1,000 patient 
days in 2014; P>.05), despite the fact that a statistically 
significant difference (c2 = 16.0481, P < .001) emerged 
between the percentages of patients classified as be-
ing at high infective risk in 2013 (32.00%) and in 2014 
(63.89%). 
Following laboratory identification of CRKP, the mem-
bers of the Hospital Infections Committee implemented 
the interventions deemed necessary, with particular re-
gard to the application of isolation measures, the disin-
fection of environmental surfaces and improvement of 
hand hygiene compliance. Indeed, eliminating surface 
contamination as a source of patient-to-patient trans-
mission of nosocomial pathogens requires multiple in-
terventions aimed at cleaning/disinfecting the environ-
ment and improving adherence to hand hygiene guide-
lines [35-37]. 
The mortality rate due to all causes of infection was 24% 
in 2013 and 37.5% in 2014. This increase, albeit not sta-
tistically significant, may have been due to the greater 
complexity of patients in the second year of observa-
tion. In any case, the mortality rates, however evaluated, 
proved to be in line with the literature data, which report 
mortality rates between 26% and 44 % [12, 38, 39].
Moreover, it emerged that the infective event most fre-
quently associated with death was bacteremia; this is 
in agreement with the results of previous studies; in a 
matched retrospective, historical cohort design study in-
volving 319 patients with infections due to carbapenem-
resistant K. pneumoniae, Borer et al. [40] found a similar 
mortality risk ratio: 3.3 (95% CI 2.9-28.5) among case 
subjects with carbapenem-resistant K. pneumoniae bac-
teremia. 
The results of our study revealed that 26% of strains 
proved resistant to colistin, a lower value than those re-
ported in similar studies [41, 42].
Regarding the results of genotyping, it emerged that the 
allelic profile most frequently observed in the hospital 
was ST 512; this is in line with the results of other stud-
ies conducted in Italy [43]. ST 512 (allelic profile: 54-
3-1-1-1-1-79) is a single-locus variant of ST 258 (allelic 
profile: 3-3-1-1-1-1-79) and is the clone most frequently 
associated worldwide with the spread of KPCs.
The ST 512 detected in the present study mainly pro-
duces KPC-3 carbapenemase; the blaKPC-3-containing 
strain of K. pneumoniae displays an exceptional combi-
nation of multidrug resistance, virulence and ability to 
spread  [44] and the KPC-3-producing K. pneumoniae 
ST 512 clone has emerged as a successful new lineage, 
capable of disseminating KPC-3 in Europe [45].
The results of the present study revealed that the charac-
teristics of the predominant strain, together with the high 
levels of comorbidity of the patients involved and the 
difficulty of ensuring structural isolation owing to the 
small number of dedicated rooms, have, at least in part, 
undermined the success of the measures for prevention 
and control adopted in the hospital.
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